On May 23, Redburn Atlantic turned bullish on Charles River Laboratories International, Inc. (NYSE:CRL) as it upgraded its stock from “Neutral” to “Buy,” despite marginally reducing the price objective to $182 from $188.
The upgrade was seen off the back of an improvement in demand in Charles River Laboratories International, Inc.’s Discovery and Safety Assessment (DSA) business. Furthermore, Elliott Management is the company’s largest investor. This, along with the announcement of a comprehensive strategic review, is seen as a catalyst for future performance.
A laboratory scientist surrounded by drug-discovery equipment and resources.
Also, the valuation profile of Charles River Laboratories International, Inc. is being aided by its leading position in the broader market and expectation of a growth trajectory after the demand normalizes. Additionally, the firm believes that its Q1 2025 report demonstrated the initial signs of improvement in demand.
Redburn Atlantic opines that the stock’s current valuation hints at a 36% discount to its 10-year average historical forward multiple. The signs of demand stabilization were highlighted by a strong improvement in DSA booking activity. Charles River Laboratories International, Inc. believes that its long-standing hallmarks of advancing scientific innovation and driving greater efficiency in the clients’ drug development programs are expected to present numerous future opportunities.
Charles River Laboratories International, Inc. is engaged in providing drug discovery, non-clinical development, and safety testing services.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now
Hedge Fund Resource Center